Ensign Peak Advisors
IGMS

Ensign Peak Advisors’s IGM Biosciences IGMS Stock Holding History

Ensign Peak Advisors’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,890
Closed -$43K – 1980
2022
Q3 		$43K Buy
1,890
+410
+28% +$8.28K ﹤0.01% 2236
2022
Q2 		$27K Sell
1,480
-45,388
-97% -$809K ﹤0.01% 2113
2022
Q1 		$1.25M Hold
46,868
– – ﹤0.01% 1079
2021
Q4 		$1.37M Sell
46,868
-148,737
-76% -$7.39M ﹤0.01% 1117
2021
Q3 		$12.9M Sell
195,605
-1,373
-0.7% -$105K 0.03% 386
2021
Q2 		$16.4M Buy
196,978
+13,500
+7% +$1M 0.03% 346
2021
Q1 		$14.1M Buy
183,478
+125,038
+214% +$11.4M 0.03% 360
2020
Q4 		$5.16M Sell
58,440
-14,192
-20% -$998K 0.01% 599
2020
Q3 		$5.36M Buy
72,632
+2,044
+3% +$121K 0.01% 611
2020
Q2 		$5.15M Buy
70,588
+2,936
+4% +$178K 0.01% 603
2020
Q1 		$3.8M Sell
67,652
-6,584
-9% -$289K 0.01% 593
2019
Q4 		$2.83M Buy
+74,236
New +$1.86M 0.01% 884

Other funds holding IGMS

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Ensign Peak Advisors's IGMS Position: Q4 2022 in Review

Ensign Peak Advisors sold out of IGM Biosciences (IGMS) in Q4 2022, closing a stake of 1,890 shares — an estimated $43K sold.

Ensign Peak Advisors first reported a position in IGMS in Q4 2019 and held it in 12 quarters. The position peaked at $16.4M in Q2 2021. 82 funds tracked by Wall St. Rank hold IGMS as of Q4 2022.

  • Ensign Peak Advisors reported no remaining IGM Biosciences position as of Q4 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 1,890 IGM Biosciences shares in Q4 2022, an estimated $43K.
  • Ensign Peak Advisors first reported a position in IGM Biosciences in Q4 2019 and held it in 12 quarters.
  • Ensign Peak Advisors's IGM Biosciences position peaked at $16.4M in Q2 2021.
  • 82 funds tracked by Wall St. Rank held IGM Biosciences as of Q4 2022.

Based on Ensign Peak Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.